Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20530226 | 0.99 | HTR6 (0.40) | HTR6DRD2ELAVL1LMNATSHR | |
| Abeprazan SCHEMBL29443418 | 0.93 | HTR6 (0.39) | HTR6DRD2SMN1; SMN2HTR2A | |
| Abeprazan SCHEMBL18196939 | 0.93 | HTR6 (0.39) | HTR6DRD2SMN1; SMN2HTR2A | |
| Abeprazan SCHEMBL29719476 | 0.93 | HTR6 (0.39) | HTR6DRD2SMN1; SMN2HTR2A | |
| SCHEMBL18196927 | 0.93 | HTR6 (0.40) | HTR6DRD2ELAVL1LMNATSHR | |
| Abeprazan SCHEMBL19385615 | 0.92 | HTR6 (0.40) | HTR6DRD2SMN1; SMN2HTR2A | |
| SCHEMBL18196918 | 0.92 | SCN9A (0.37) | HTR6DRD2 | |
| Hydrochloric Acid SCHEMBL20530202 | 0.92 | HTR6 (0.40) | HTR6DRD2ELAVL1LMNATSHR | |
| Hydrochloric Acid SCHEMBL20530239 | 0.91 | SCN9A (0.36) | HTR6DRD2HTR2A | |
| SCHEMBL18190937 | 0.91 | HTR6 (0.35) | HTR6DRD2NPC1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197867-B1 | NOVEL 4-METHOXY PYRROLE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2018-11-14 | — | — | EP | claimed |
| US-10100010-B1 | 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-16 | — | — | US | claimed |
| EP-3197867-B1 | NOVEL 4-METHOXY PYRROLE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2018-11-14 | — | — | EP | disclosed |
| US-10100010-B1 | 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-16 | — | — | US | disclosed |
| WO-2016175555-A2 | NOVEL 4-METHOXY PYRROLE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100010-B1 | 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | GIPR, GRPR, HTR3E | HTR6 38/4885DRD2 127/4885ELAVL1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.